ArticleThe Journal of experimental medicine1996
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 90 citations in OpenAlex.
- Ubiquitination regulates expression of the serine/arginine-rich splicing factor 1 (SRSF1) in normal and systemic lupus erythematosus (SLE) T cells.The Journal of biological chemistry · 2014Trial
- Trial
- Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci.Nature communications · 2024Article
- An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.Frontiers in immunology · 2022Article
- Role of Proteasomes in Inflammation.Journal of clinical medicine · 2021Review
- An Autoantigen-ome from HS-Sultan B-Lymphoblasts Offers a Molecular Map for Investigating Autoimmune Sequelae of COVID-19.bioRxiv : the preprint server for biology · 2021Article
- Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis.RMD open · 2020Article
- A comprehensive autoantigen-ome of autoimmune liver diseases identified from dermatan sulfate affinity enrichment of liver tissue proteins.BMC immunology · 2019Article
- Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Differentially expressed lncRNAs and mRNAs identified by microarray analysis in GBS patients vs healthy controls.Scientific reports · 2016Article
- Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Arthritis research & therapy · 2015Review
- Haem oxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus.Immunology · 2012Article
- Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus.Clinical and vaccine immunology : CVI · 2008Article
- Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells.Annals of the rheumatic diseases · 2007Article
- Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.Annals of the rheumatic diseases · 2006Article
- Limkain b1, a novel human autoantigen localized to a subset of ABCD3 and PXF marked peroxisomes.Clinical and experimental immunology · 2005Article
- The role and clinical implications of G6PI in experimental models of rheumatoid arthritis.Arthritis research & therapy · 2005Review
- Proteasome inhibition: a new anti-inflammatory strategy.Journal of molecular medicine (Berlin, Germany) · 2003Review
- Idiopathic inflammatory myopathy: autoantibody update.Current rheumatology reports · 2002Review
- Proteasome inhibition: a new strategy in cancer treatment.Investigational new drugs · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantibodies occur in low frequencies among patients with myositis characterizing only distinct subsets of this disease. Most of these known antibodies are directed to enzymatically active complexes. The 20S proteasome represents an essential cytoplasmatic protein complex for intracellular nonlysosomal protein degradation, and is involved in major histocompatibility complex class I restricted antigen processing. In this study we investigated whether the 20S proteasome complex is an antibody target in myositis and in other autoimmune diseases. 34 sera of poly/dermatomyositis patients were assayed for antiproteasomal antibodies using enzyme-linked immunosorbent assay, immunoblot, and two-dimensional non-equilibrium pH gradient electrophoresis (NEPHGE). Sera was from patients with systemic lupus erythematosus (SLE), mixed connective tissue disease, and rheumatoid arthritis; healthy volunteers served as controls. In 62% (21/34) of the cases sera from patients with myositis and in 58% (30/52) of the cases sera from patients with SLE reacted with the 20S proteasome. These frequencies exceeded those of sera from patients with mixed connective tissue disease, rheumatoid arthritis, and healthy controls. The alpha-type subunit C9 of the 20S proteasome was determined to be the predominant target of the autoimmune sera in myositis and SLE. Lacking other frequent autoantibodies in myositis, the antiproteasome antibodies are the most common humoral immune response so far detected in this disease entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.